No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Gubra A/S is a biotechnology firm engaged in two core activities: offering contract research organization (CRO) services for pre-clinical development, and advancing its own internal early-stage drug and target discovery initiatives. Its CRO division provides specialized pre-clinical research and development support to companies in the pharmaceutical and biotechnology sectors. These services encompass a wide range of capabilities, including in vivo pharmacology, tissue analysis, various assay development, molecular pharmacology, bioanalytical testing, next-generation sequencing (NGS), and both two-dimensional and three-dimensional imaging techniques. Established in 2008, the company has its headquarters in Horsholm, Denmark.
www.gubra.dkNo one on the platform currently holds GUBRA.CO.
No tracked institution reports a position in GUBRA.CO as of their last filing.
No one on the platform has traded GUBRA.CO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 142.7% | — | — | — | ||
| Rev. Growth % | 892.2% | 72.6% | ||||
| Profit Margin % | 64.1% | 11.5% | ||||
| Free Cash Flow Margin % | 64.3% | 10.7% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $576M | -78.1% | $-2.50 | $-3.39–$-1.61 | — | 2 |
| 2027 | $635M | +10.2% | $-3.58 | $-43.76–$36.61 | — | 2 |
| 2028 | $1.0B | +60.0% | $25.15 | $11.46–$46.46 | — | 3 |
| 2029 | $664M | -34.6% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-20 | $-5.01 | $-6.70 | -33.7% |
| 2026-02-27 | $-0.06 | $-4.40 | -7233.3% |
| 2025-08-21 | $145.77 | $107.10 | -26.5% |
| $8.7B |
| — |
| MONSO.COMonsenso A/S | $0.25 | -1.57% | $17M | — |
| PEG.COPharma Equity Group A/S | $0.08 | +0.00% | $97M | — |
Source: Financial Modeling Prep · peers by sector/industry